Compare LFST & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFST | SRPT |
|---|---|---|
| Founded | 2015 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.5B |
| IPO Year | 2021 | 2000 |
| Metric | LFST | SRPT |
|---|---|---|
| Price | $10.10 | $16.17 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 29 |
| Target Price | $9.83 | ★ $25.85 |
| AVG Volume (30 Days) | ★ 2.8M | 2.8M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | $1,424,285,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $17.18 | N/A |
| Revenue Next Year | $14.02 | N/A |
| P/E Ratio | ★ N/A | $5.56 |
| Revenue Growth | 13.85 | ★ 15.58 |
| 52 Week Low | $3.74 | $10.42 |
| 52 Week High | $10.00 | $25.32 |
| Indicator | LFST | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 78.65 | 43.75 |
| Support Level | $6.23 | $15.10 |
| Resistance Level | N/A | $18.16 |
| Average True Range (ATR) | 0.33 | 0.79 |
| MACD | 0.17 | 0.18 |
| Stochastic Oscillator | 97.66 | 42.57 |
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.